Article of Significant Interest Selected from This Issue by the Editors

A Single High Dose of CVD 103-HgR Live Oral Cholera Vaccine Is More Immunogenic than a Standard Dose or than One or Two Doses of Shanchol Oral Killed Vaccine

In a study by Sow et al. (e00265-17), Malian adults were randomly allocated to receive a single standard dose (108 CFU) or a high dose (109 CFU) of CVD 103-HgR live oral cholera vaccine or two doses (2 weeks apart) of Shanchol killed oral cholera vaccine. Inaba serum vibriocidal antibody responses (seroconversion rate, geometric mean titer [GMT], and fold rise) were compared. High-dose CVD 103-HgR exhibited significantly higher seroconversion rates than one or two doses of Shanchol and significantly higher GMTs than standard-dose CVD 103-HgR. A single high dose of CVD 103-HgR is recommended for accelerated evaluation in developing countries to assess effectiveness and practicality in field situations.

Top, percentage of vaccinees in each group who seroconverted by days of follow-up; middle, kinetics of the GMT of serum vibriocidal antibody by days of follow-up; bottom, kinetics of the geometric mean fold rise (GMFR) of serum vibriocidal antibody by...

Articles from Clinical and Vaccine Immunology : CVI are provided here courtesy of American Society for Microbiology (ASM)